Kimberly Earl, APRN
Psychiatric/Mental Health · Springfield, ILNPI 1063669497
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 338 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 338 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Supernus Pharmaceuticals, Inc.$998
- Takeda Pharmaceuticals U.S.A., Inc.$762
- Corium, LLC$575
- Lundbeck LLC$517
- Axsome Therapeutics, Inc.$420
- plus $2K from 14 others
What the payments were for
- Food & beverage$6,65898%
- Education$1072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 69 | $1,358 |
| Supernus Pharmaceuticals, Inc. | 50 | $998 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $762 |
| Corium, LLC | 31 | $575 |
| Lundbeck LLC | 23 | $517 |
| Axsome Therapeutics, Inc. | 18 | $420 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $414 |
| Neurocrine Biosciences, Inc. | 15 | $319 |
| Alkermes, Inc. | 9 | $252 |
| Sunovion Pharmaceuticals Inc. | 21 | $235 |
| Ironshore Pharmaceuticals Inc. | 9 | $207 |
| Otsuka America Pharmaceutical, Inc. | 9 | $201 |
| Teva Pharmaceuticals USA, Inc. | 4 | $96 |
| Jazz Pharmaceuticals Inc. | 5 | $84 |
| Johnson & Johnson | 4 | $83 |
| Vanda Pharmaceuticals Inc. | 3 | $80 |
| E.r. Squibb & Sons, L.L.C. | 3 | $65 |
| Biogen | 3 | $46 |
| Eisai Inc. | 2 | $40 |
| Almatica Pharma LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,765 in reported general payments places this provider in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 14 | $105,810 |
| VraylarCariprazine Hcl | 30 | $60,411 |
| TrintellixVortioxetine Hydrobromide | 38 | $30,143 |
| AzstarysSerdexmethylphen/Dexmethylphen | 14 | $5,727 |
| Aripiprazole | 32 | $1,963 |
| Duloxetine Hcl | 79 | $1,729 |
| Buspirone Hcl | 45 | $1,429 |
| Bupropion XlBupropion Hcl | 60 | $1,153 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 21 | $906 |
| Trazodone Hcl | 68 | $534 |
| Bupropion Hcl SrBupropion Hcl | 15 | $507 |
| Guanfacine Hcl | 11 | $459 |
| Escitalopram Oxalate | 30 | $432 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 28 | $420 |
| Methylphenidate Hcl | 12 | $313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $96 | $105,81014 claims |
| AbbVieVraylar | $1,358 | $60,41130 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $762 | $30,14338 claims |
| Corium, LLCAzstarys | $575 | $5,72714 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $21445 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Other psychiatric/mental health in Springfield
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$151K
- Melissa VitaleChicago$151K
- Alan AmbergChicago$119K
- Jaime MendozaMaryville$111K
- Jennifer TheryMaryville$83K
- Carole Weddington HuntGranite City$67K
- Jessica WhelanBloomington$55K
- Lynn LochnerKankakee$41K
- Julie CarbrayChicago$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.